Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
Orgenesis Inc. issued warrant to purchase 15% of the fully diluted share capital of warrant to Alpha Prosperity Fund SPC, acting on behalf of and for the account of Segregated Portfolio P for aggregate exercise price equal to $250,000.
- Security
- warrant
- Shares
- warrant to purchase 15% of the fully diluted share capital
- Purchaser
- Alpha Prosperity Fund SPC, acting on behalf of and for the account of Segregated Portfolio P
- Consideration
- aggregate exercise price equal to $250,000
Exact text from the filing
issue to Lender a warrant to purchase 15% of the fully diluted share capital of either the Company or Theracell, at the Lender’s discretion, for an aggregate exercise price of $250,000 and exercisable for three years from issuance with respect to each cumulative drawdown of $1,000,000 under the loan and credit facility referenced above. With respect to the first
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Orgenesis Inc. entered into Convertible Loan Agreement with Alpha Prosperity Fund SPC, acting on behalf of and for the account of Segregated Portfolio P valued at $1,000,000 convertible loan, a $10,000,000 credit facility (effective 2025-09-10).
- Action
- entry
- Agreement
- credit facility
- Counterparty
- Alpha Prosperity Fund SPC, acting on behalf of and for the account of Segregated Portfolio P
- Value
- $1,000,000 convertible loan, a $10,000,000 credit facility
- Effective
- 2025-09-10
Exact text from the filing
Orgenesis Inc. (the “Company”) entered into that certain Convertible Loan Agreement, dated September 10, 2025, by and among Theracell Laboratories IKE, the Company and Alpha Prosperity Fund SPC, acting on behalf of and for the account of Segregated Portfolio P (the “Lender”) with respect to a $1,000,000 convertible loan, a $10,000,000 credit facility
View on SEC.gov